Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01788228 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
A Phase 3 study of Influenza and Influenza Vaccines, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT01788228 is a Phase 3 study of Influenza and Influenza Vaccines that has completed, run by GlaxoSmithKline. The registered enrollment target is 50 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01788228, a Phase 3 study of Influenza and Influenza Vaccines, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of GSK Biologicals' vaccine GSK1557484A against pandemic avian (H5N1) influenza in adults at occupational risk of exposure to the virus.
Conditions Studied
Interventions
- BIOLOGICAL Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
Study Locations (3)
Georgia
- GSK Investigational Site - Stockbridge
Maryland
- GSK Investigational Site - Rockville
Wisconsin
- GSK Investigational Site - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-03-22 |
| Est. Completion | 2015-02-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01788228
The ClinicalTrials.gov registry entry for NCT01788228 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) is the first listed.
NCT01788228 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Georgia, Maryland, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01788228 about?
NCT01788228 is a clinical study titled "Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure". The purpose of this study is to evaluate the safety and tolerability of GSK Biologicals' vaccine GSK1557484A against pandemic avian (H5N1) influenza in adults at occupational risk of exposure to the virus.
What is the current status of trial NCT01788228?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2013-03-22. Estimated completion is 2015-02-25.
What conditions does trial NCT01788228 study?
This clinical trial studies the following conditions: Influenza, Influenza Vaccines.
What interventions are being tested in trial NCT01788228?
The interventions under investigation include: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01788228?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01788228 being conducted?
This trial has 3 study locations across Georgia, Maryland, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
RECRUITING · Phase 3
-
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
COMPLETED · Phase 3
-
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
COMPLETED · Phase 3
-
Study of Quadrivalent Influenza Vaccine Among Children
COMPLETED · Phase 3
-
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.